Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
CONTRACEPTIVE DRUGS AND DEVICES MARKET- GROWTH, TRENDS, AND FORECAST (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| 111 pages | Published: 01-03-2019 |
- Healthcare
- Mordor Intelligence
- Global
- 111 pages
- Published: 01-03-2019
Sample
The global interactive whiteboard market size was valued at USD 1.51 billion in 2018 and is anticipated to expand at a CAGR of 6.8 % from 2019 to 2025. Rising adoption of advanced learning methods is one of the factors positively affecting the IWB usage. These boards provide an adaptive, engaging, and user-friendly learning experience and are therefore gaining popularity among various sectors, such as government, corporate, and education. Digital learning has transformed conventional classroom teaching.
The emergence of virtual classrooms and e-learning courses has resulted in an increased demand for IWBs. The e-learning industry has witnessed a significant growth over the last decade due to the rapid evolution of digitization, communication, and other technological advancements that are cost-effective and are easily available for a wider audience. Furthermore, significant investments in Information and Learning Technology (ILT) infrastructure in colleges, development of digital content and mobile learning applications, and national training initiatives have transformed the traditional chalk and board learning and teaching methods.
1. INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of the STDs
4.2.2 Increasing Rate of Unintended Pregnancies
4.2.3 Rise in Government Initiatives
4.3 Market Restraints
4.3.1 High Cost of Devices and Treatment
4.3.2 Side Effects Associated with the Use of Contraceptive Drugs and Devices
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Products
5.1.1 By Drugs
5.1.1.1 Oral Contraceptives
5.1.1.2 Topical Contraceptives
5.1.1.3 Contraceptive Injectable
5.1.2 By Device
5.1.2.1 Condoms
5.1.2.2 Diaphragms
5.1.2.3 Cervical Caps
5.1.2.4 Sponges
5.1.2.5 Vaginal Rings
5.1.2.6 IUD
5.1.2.7 Others
5.2 By Gender
5.2.1 Male
5.2.2 Female
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer Healthcare
6.1.2 Pfizer
6.1.3 Merck & Co.
6.1.4 Teva Pharmaceuticals Ltd
6.1.5 Agile Therapeutics
6.1.6 Allergan PLC
6.1.7 Ani Pharmaceuticals Inc.
6.1.8 Church & Dwight Co. Inc.
6.1.9 Fuji Latex Co. Ltd
6.1.10 Johnson & Johnson Ltd
*List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Market Segmentation
- Interactive Whiteboards Technology Outlook (Revenue, USD Million, 2014 – 2025)
- Infrared
- Resistive Membrane
- Electromagnetic Pen
- Capacitive
- Others
- Interactive Whiteboards Form Factor Outlook (Revenue, USD Million, 2014 – 2025)
- Fixed
- Portable
- Interactive Whiteboards Projection Technique Outlook (Revenue, USD Million, 2014 – 2025)
- Front Projection
- Rear Projection
- Interactive Whiteboards Application Outlook (Revenue, USD Million, 2014 – 2025)
- Education
- Corporate
- Commercial
- Others
Why choose us
-
24/5 Research supportGet your queries resolved from an industry expert.
-
Custom research serviceDesign an exclusive study to serve your research needs.
-
Quality assuranceA testimonial for service in the form of BBB “A” Accreditation.
-
Information securityYour personal and confidential information is safe and secure.
Diagnostic Imaging Market – Segmented by Type (X-Ray, MRI, Nuclear Medicine, Ultrasound, Tomography, Tactile Imaging, Thermography & Others), By Application (Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology), By Geography – Analysis and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| Unknown | Published: 21-06-2019 |
- Healthcare
- Mordor Intelligence
- Global
- pages
- Published: 21-06-2019
Diagnostic Imaging Market
The market has been estimated at USD XX billion for the year 2016 and is projected to reach USD XX billion by the end of 2021 at a CAGR of XX% during the forecast period from 2016 to 2021.
Medical imaging is the process of making a visual representation of the interior of the body for medical intervention. These instruments help in establishing a database of normal anatomy and physiology of internal organs so that any abnormality can be noticed immediately. The ability to create pictures of a patient’s internal anatomy and convert them to film through diagnostic imaging has revolutionized the way many diseases and injuries are detected, diagnosed, and treated. This market has applications in various medical fields like cardiology, oncology, neurology, and orthopedics. Globally, most of the industrialized countries are spending a large part of their GDP on healthcare requirements. The US is set to spend nearly 20% of its GDP on healthcare by 2017, a higher percentage than any other industrialized nation.
Wider adoption of cloud technologies and adoption of new advanced technologies play a major role in improving the market economy. Increasing aging populations and increased incidence of chronic diseases are also key factors driving the market. According to the National Institutes of Health, patients aged 65 and older undergo diagnostic imaging at two or more times the rate of younger people. Women also tend to use slightly higher rates of imaging than men. In spite of these factors driving the market, there are other factors constraining the growth of the market. Expensive procedures & equipment, side effects of diagnostic imaging procedures and saturation in the developed regions are the major challenges faced by the diagnostic imaging equipment market.
There are several new developments afoot in the medical imaging world. Imaging science is a dynamic, evolving field of multi- and interdisciplinary activities with a lot of scope and importance. Due to the increasing need to operate more efficiently and productively, medical imaging facilities will increasingly turn towards data analytics. There will be growing interest and demand for analytics solutions. PACS, RIS, and dictation systems are driving this market currently and are anticipated to emerge economically in coming years.
The market is segmented based on type (X-ray, MRI, nuclear medicine, ultrasound, tomography, tactile imaging, photoacoustic imaging, thermography, elastography, echocardiography, and functional near infrared spectroscopy). A few segments are sub-divided based on portability, structure, technology and resolution.
Tomosynthesis is another prominently used method. According to the Radiological Society of North America, tomosynthesis, or 3D mammography increases cancer detection and reduces the instances of the patient being called for further tests. 3D imaging is expected to grow in all markets during the forecast period. Manufacturers are showing a keen interest in improving image quality by exploiting new technologies and producing new instruments or novel techniques to achieve images with higher spatial resolution. Imaging will continue to advance and provide an essential set of tools for clinical research, drug development, disease diagnosis, treatment and assessing treatment response.
Based on geography, the global diagnostic imaging market is divided into North America, Europe, Asia-Pacific, Middle East & Africa and Latin America. Currently, North America dominates the market with nearly 20% of the gross domestic product spent on healthcare by the USA. Asia-Pacific is a market that is expected to grow at a faster rate, owing to the rapidly aging population and increase in the chronic disease population.
Medical imaging technology is a rapidly changing field, and healthcare organizations have multiple options for new acquisitions. Many players in this market are trying to expand their product portfolio in order to top the global market. A few companies have adopted product innovation and new product launches as their key business strategy to ensure their dominance in this market.
Key Deliverables in the Study
Market analysis for the diagnostic imaging market, with region specific assessments and competition analysis on the global and regional scale.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
Identification and analysis of the macro and micro factors that affect the global diagnostic imaging market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Medical Imaging Industry Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Rise in the Prevalence of Chronic Diseases
6.1.2 Increased Adoption of Advanced Technologies in Medical Imaging
6.1.3 Increase in the Geriatric Population
6.2 Restraints
6.2.1 Expensive Procedures and Equipment
6.2.2 Side Effects of Diagnostic Imaging
6.2.3 Slower Growth in Developed Regions
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 Medical Imaging Market – Product Type
7.1.1 X-Ray Equipment
7.1.1.1 Stationary
7.1.1.2 Portable
7.1.2 Fluoroscopy
7.1.2.1 Fixed Fluoroscope
7.1.2.2 Mobile Fluoroscope
7.1.3 MRI
7.1.3.1 Closed Systems
7.1.3.2 Open Systems
7.1.4 Ultrasound
7.1.5 Computed Tomography
7.1.6 Other Imaging Modalities
7.2 Medical Imaging Market – By Application
7.2.1 Cardiology
7.2.2 Oncology
7.2.3 Neurology
7.2.4 Orthopedics
7.2.5 Gastroenterology
7.2.6 Gynecology
7.2.7 Other Applications
7.3 Medical Imaging Market – By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisitions Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Carestream Health Inc.
9.2 Esoate SpA
9.3 Fujifilm Holding
9.4 GE Healthcare
9.5 Hitachi Medical Systems
9.6 Hologic Corporation
9.7 Philips Healthcare
9.8 Shimadzu Medical
9.9 Siemens Healthcare
9.10 Canon Medical Systems Corporation
*List not Exhaustive
10. Future of the Marke
Market Segmentation
Medical Imaging Market – Product Type
X-Ray Equipment
Stationary
Portable
Fluoroscopy
Fixed Fluoroscope
Mobile Fluoroscope
MRI
Closed Systems
Open Systems
Ultrasound
Computed Tomography
Other Imaging Modalities
Medical Imaging Market – By Application
Cardiology
Oncology
Neurology
Orthopedics
Gastroenterology
Gynecology
Other Applications
Medical Imaging Market – By Geography
North America
United States
Canada
Mexico
Europe
France
Germany
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of the Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Market Entry – Electronic Aspirin Industry in Vietnam: Analysis of Growth, Trends and Progress (2016 – 2021)
| Financial Services & Investment Intelligence | Published by: Mordor Intelligence | Market: Việt Nam |
| Unknown | Published: 24-06-2019 |
- Financial Services & Investment Intelligence
- Mordor Intelligence
- Việt Nam
- pages
- Published: 24-06-2019
Market Overview
Each country envisages and aspires a greater economic dynamism and prosperity. And wants to be a creditor nation than being a debtor nation. But that is not easy to achieve. It depends on respective government’s public policy, political and sovereign power and the overall laws of the country.
Lasting prosperity is a result of a persistent commitment to low tax rates, a stable currency, limited government, strong private property rights, open to global trade and financial flows, and sensible regulation.
Mordor Intelligence has the world’s most inclusive research on the Electronic Aspirin market. We monitor and analyze industry trends around the world, including strategy for market entry, in-depth analysis on market share and market size – from qualitative analysis to qualitative with market data. Mordor Intelligence data and market analysis supports your organization’s awareness of the Electronic Aspirin market and the greater competitive atmosphere, ensuring accurate and focused strategies for your business.
Report on Electronic Aspirin market helps the organizations looking forward towards market entry. It also helps existing organizations and entities and supports in strategy formation for nurturing your business.
A resource for your entire organization, Mordor Intelligence market research supports every level of business, assisting in strategic development, marketing, mergers and acquisitions, and brand management.
Electronic Aspirin industry in Vietnam is a fast growing sector and can become an important source of earning for the nation. Domestic Electronic Aspirin Market, focuses on the development and enhancement of production facilities, factories and market (storage and distribution) in the country. There have been a remarkable progress in the field of Electronic Aspirin in the past 5 years. Vietnam’s focus on improving healthcare facilities have resulted in growth of Electronic Aspirin in the country. Advanced Technology and instant healthcare needs in the country have impacted the Electronic Aspirin industry in positive ways.
With a population of 89.71 million, Vietnam is one of the biggest economy in the world. Even though Vietnam faced some economic problem in 2008 economic crisis; the country has high per capita income of USD 1,910. The country also has a favorable demographic structure needed for its fast scaled growth. Electronic Aspirin Market is expected to grow at a CAGR of XX.XX% till 2020.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Scope of the Report
1.2 Regional Analysis
1.2.1 PESTLE Analysis
1.2.2 Analysis of Ease of Doing Business
2. Market Dynamics
2.1 Drivers
2.2 Restraints
2.3 Opportunities
3. Market Demand Analysis
3.1 Socio-Economic Segmentation
3.2 Demographic Strengths & Weaknesses
3.3 Spending Patterns
3.4 Target Market Identification
4. Market Size of Electronic Aspirin Industry (USD millions)
5. Market Entry
5.1 Market Entry: The Strategy
5.1.1 Types of Entry Modes, by Market Entry Objectives
5.1.2 Competition Analysis
5.1.2.1 Market Share
5.1.2.2 Strategies Adopted, Recent Events
5.1.3 Pricing Strategy
5.1.4 Supply Chain Analysis
5.1.4.1 Trade (Import-Export Analysis)
5.1.4.2 Distribution Network & Retail Analysis
5.2 Market Entry: The Administration
5.2.1 How to Register a Company (Flowchart)
5.2.2 Registration Processes
5.2.2.1 Ministries Involved
5.2.2.2 Criteria and Conditions
5.2.3 List of Forms & Documents
5.2.4 Product Control Guidelines specified by the Government
6. Sources
7. Disclaime
Market Segmentation by Market Entry
The Strategy
Types of Entry Modes, by Market Entry Objectives
Competition Analysis
Market Share
Strategies Adopted, Recent Events
Pricing Strategy
Supply Chain Analysis
Trade (Import-Export Analysis)
Distribution Network & Retail Analysis
The Administration
How to Register a Company (Flowchart)
Registration Processes
Ministries Involved
Criteria and Conditions
List of Forms & Documents
Product Control Guidelines specified by the Government
CLINICAL TRIALS MARKET- GROWTH, TRENDS, AND FORECAST (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| 117 pages | Published: 24-06-2019 |
- Healthcare
- Mordor Intelligence
- Global
- 117 pages
- Published: 24-06-2019
Market Overview
The major factors found propelling the growth of the market include the high demand for clinical trials in emerging markets, high R&D spending of the pharmaceutical industry, an increasing prevalence of diseases, and the focus on rare diseases and multiple orphan drugs in the pipeline.
The market is growing at a robust pace, owing to the advancements in healthcare and growing patented new chemical entities (NCE) indicated for various health conditions.
It has also been found that there are a large number of unmet clinical needs in emerging countries, due to the prevalence of infectious and tropical diseases in the region. Owing to these, a large number of the population participate in clinical trials to access high-quality healthcare free of cost. India and China have the highest prevalence rates for metabolic disorders, due to the increasing population, combined with the prevalence of insulin resistance, hyperlipidemia, and obesity.
In addition, government initiatives have also motivated the small, medium, and large players to enter into orphan drug development. Thus, there are multiple drugs in the pipeline. As a result, Novartis, GlaxoSmithKline, and Pfizer (among others) have entered this field. It has also been found that the clinical trials market has taken bigger strides in the developing countries of Asia-Pacific and the Middle East and there is still very less development in the market.
Scope of the Report
As per the scope of the report, clinical trials are experiments that are conducted under clinical research and follow a regulated protocol. These experiments are primarily performed to obtain data regarding the safety and efficacy of newly developed drugs. Clinical trial data is mandatory for drug approval, as well as for it to be introduced in the market. These trials are performed under three phases (I, II, and III), which depends upon various factors. This process is not only expensive, but also time consuming, and requires expertise at all stages.
Key Market Trends
Phase III is the Largest Segment Under Phases that is Expected to Grow During the Forecast Period
The market is expected to be dominated by Phase III, with Phase I expected to witness the fastest growth. Phase III is one of the most critical phases assessing the effectiveness of the new intervention, as well as its value in clinical practice. The Phase I trial in the market studied is also expected to grow at a steady rate, due to the increasing number of investigative new drug (IND) applications filed. The government initiatives in emerging economies for the promotion of drug discovery and continuous technological innovations are expected to propel the market growth.
North America has been Reported with the Largest Growth that is Expected to Follow the Same Trend over the Forecast Period
North America dominated the overall market, owing to the presence of big outsourcing firms and increasing R&D in the region. However, increasing R&D investments and an increasing demand for drug development are the major factors responsible for the market emergence in the United States.
Competitive Landscape
The major pharmaceutical companies are found making enormous investments in R&D, especially in the emerging nations, in order to gain opportunities for market growth in the major regions. The strategic partnerships among pharmaceutical companies and the CROs are expected to have a significant impact on the market’s growth.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Demand for Clinical Trials in the Emerging Markets
4.2.2 High R&D Expenditure of the Pharmaceutical Industry
4.2.3 Rising Prevalence of Diseases
4.2.4 Focus on Rare Diseases and Multiple Orphan Drugs in the Pipeline
4.3 Market Restraints
4.3.1 Lack of Skilled Workforce Clinical Research
4.3.2 Lower Healthcare Reimbursement in the Developing Countries
4.3.3 Stringent Regulations for Patient Enrollment
4.4 Porter’ s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Design
5.2.1 Treatment Studies
5.2.1.1 Randomized Control Trial
5.2.1.1.1 Double Blind Trial Randomized Trial
5.2.1.1.2 Single Blind Trial Randomized Trial
5.2.1.1.3 Non-blind Randomized Trial
5.2.1.2 Adaptive Clinical Trial
5.2.1.3 Non-randomized Control Trial
5.2.2 Observational Studies
5.2.2.1 Cohort Study
5.2.2.2 Case Control Study
5.2.2.3 Cross Sectional Study
5.2.2.4 Ecological Study
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Clinipace
6.1.2 Laboratory Corporation of America
6.1.3 Eli Lilly and Company
6.1.4 ICON PLC
6.1.5 Novo Nordisk AS
6.1.6 PAREXEL International Corporation
6.1.7 Pfizer Inc.
6.1.8 Pharmaceutical Product Development LLC
6.1.9 IQVIA
6.1.10 F. Hoffmann-La Roche Ltd
6.1.11 Sanofi
6.1.12 Wuxi AppTec
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Phase
Phase I
Phase II
Phase III
Phase IV
By Design
Treatment Studies
Randomized Control Trial
Double Blind Trial Randomized Trial
Single Blind Trial Randomized Trial
Non-blind Randomized Trial
Adaptive Clinical Trial
Non-randomized Control Trial
Observational Studies
Cohort Study
Case Control Study
Cross Sectional Study
Ecological Study
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Anti-Snoring Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- Global
- 118 pages
- Published: 07-06-2019
Market Overview
The anesthesia devices market was valued at USD 9,812.9 million in 2018, and it is expected to reach USD 14,783.0 million by 2024, with an anticipated CAGR of 7.11%, during the forecast period, 2019-2024.
The growth in the geriatric population is likely to result in a significant increase in the demand for the surgeries. The overall increase in the number of surgeries performed has a strong impact on the anesthesia devices market, as anesthetic devices are used in surgical procedures to reduce the pain. The geriatric population is highly prone to degenerative diseases and chronic illnesses, which has caused an increased verge on surgeries and therapeutics. This demands for continuous monitoring, and it is thus expected to drive the growth of the anesthesia devices market. Increasing investments in the market, supporting the technological advancements in anesthesia machines and techniques, are having a major impact on market growth, enabling faster deployment in the healthcare industry.
The requirement by the government, for clear documentation of regular and appropriate servicing of the anesthesia machines, including its components, and their proper maintenance, servicing, and repair, is acting as a restraining factor for the growth of the market.
Scope of the Report
As per the scope of this study, anesthesia devices are used to check a patient’s response toward anesthesia during a surgical process. The requirement of these devices depends upon the type of surgery being performed, and it differs in every case. These devices help the anesthetist to monitor the dose of anesthesia.
Key Market Trends
Anesthesia Monitors Sub-segment is Expected to Register a High CAGR in the Forecast Period
Anesthesia monitors are used to recording and display the delivery of anesthetic substances, like gases, drugs, and fluids to the patient. During surgeries, these are used to check the patients’ health and reaction to the indication of anesthesia. The integration of various functionalities, such as oxygen saturation level, carbon dioxide level, heart rate, and blood pressure, coupled with decision support systems and data analysis to aid clinicians to get better insights on their patients, is favoring the market growth.
The geriatric population is expected to reach 1,402.4 million by 2030, with the increasing life expectancy to 78.74 years (the United States). This is expected to have an indirect impact on the demand for anesthesia monitors.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall market throughout the forecast period. In the North American region, the United States holds the largest market share, and this is due to the rapid increase in a number of diseases, such as obesity, cardiovascular problems, and different types of cancers, which have contributed to the rise in the number of surgeries of both open as well as minimally invasive types. The increase in the number of minimally invasive surgeries for chronic diseases has helped the growth of the anesthesia devices market in the country.
Competitive Landscape
The anesthesia devices market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of diseases and a rising number of surgeries, few other smaller players are expected to enter into the market in the coming years. Some of the major players of the market are B. Braun Melsungen AG, Medtronic PLC, Draegerwerk AG, Koninklijke Philips NV, and Fisher & Paykel Healthcare, among others.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
Table of Contents
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements in Anesthesia Technology
4.2.2 Increasing Geriatric Population and a Rise in the Number of Surgical Procedures Requiring Anesthesia
4.2.3 Large Patient Pool Due to Chronic Diseases
4.2.4 Increasing Disposable Incomes in Emerging Markets
4.3 Market Restraints
4.3.1 High Cost of Equipment
4.3.2 Difficulties Associated with the Usage of Anesthesia Devices
4.3.3 Reimbursement Issues in Developing Economies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Product Type
5.1.1 Anesthesia Machines
5.1.1.1 Anesthesia Workstation
5.1.1.2 Anesthesia Delivery Machines
5.1.1.2.1 Portable
5.1.1.2.2 Standalone
5.1.1.3 Anesthesia Ventilators
5.1.1.4 Anesthesia Monitors
5.2 By Disposables and Accessories
5.2.1 Anesthesia Circuits (Breathing Circuits)
5.2.2 Anesthesia Masks
5.2.3 Endotracheal Tubes (ETTs)
5.2.4 Laryngeal Mask Airways (LMAs)
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 B. Braun Melsungen AG
6.1.2 Medtronic PLC
6.1.3 Draegerwerk AG
6.1.4 Ambu A/S
6.1.5 Fisher & Paykel Healthcare
6.1.6 GE Healthcare
6.1.7 Koninklijke Philips NV
6.1.8 Mindray Medical International Limited
6.1.9 Smiths Medical
6.1.10 Teleflex Inc.
7. Market Opportunities and Future Trends
Market Segmentation
- Market Segmentation
By Product Type
Anesthesia Machines
Anesthesia Workstation
Anesthesia Delivery Machines
Portable
Standalone
Anesthesia Ventilators
Anesthesia Monitors
By Disposables and Accessories
Anesthesia Circuits (Breathing Circuits)
Anesthesia Masks
Endotracheal Tubes (ETTs)
Laryngeal Mask Airways (LMAs)
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe - Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Alpha Emitter Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- Global
- 115 pages
- Published: 07-06-2019
Market Overview
The global alpha emitter market was valued at USD 506.5 million in 2018, and it is estimated to be valued at USD 3302.99 million by 2024 while witnessing a CAGR of 36.69% over the forecast period of 2019-2024. Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy, and the growing number of patients with cardiac and cancer ailments.
Targeted anticancer or alpha therapy (TAT) is gaining popularity with the increasing prevalence of cancer and cardiovascular diseases. Consumers are now increasingly aware of the potential benefits of targeted therapies to cure such ailments.
Furthermore, radioimmunotherapy with short-ranged and high-efficiency α-particles is a striking and promising treatment approach. α-particles have an advantage in targeted therapy because of their exceptionally high cell-killing ability. However, regulatory requirements pose a hurdle to translational research and clinical investigations. For instance, in the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radiotherapeutics, undergo regulatory oversight by the FDA. Similarly, radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways, across the world.
Scope of the Report
In therapeutic radiopharmaceuticals, radionuclides with alpha emitters play a significant role in treating cancers. Properties of alpha emitters have led to exert profound differences between this field and other fields of nuclear medicine. Due to their short range and high LET (deposit energy in a unit length of their pathway), alpha particles have remarkably been considered into medical research.
Key Market Trends
Medical Application in Ovarian Cancer is Expected to Observe the Highest Growth Rate over the Forecast Period
The ovarian cancer segment in the alpha emitter market is expected to witness the highest CAGR of 35.63% during the forecast period.
The growth rate is attributed to an increasing number of new diagnosis cases. As per the estimates of the American Cancer Society, in 2018, around 22,240 women were expected to receive a new diagnosis of ovarian cancer, and about 14,070 women would die from ovarian cancer.
Ovarian cancer uses radioimmunotherapy as locally injected adjuvant therapy. Trials have evaluated the practice of complete abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific i.p. radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant therapies.
Moreover, the adoption of targeted alpha therapy with higher LET and shorter wavelengths has been promising in the treatment process. This trend is expected to gain traction in the near future. In addition, a recent Phase I clinical trial involving At-211-MX35 F (ab′) showed significant efficacy, as therapeutic doses reached their targets in patients with ovarian cancer.
North America Dominates the Market and is Expected to do Same in the Forecast Period
North America currently dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that the increase in cardiac and neurological chronic diseases is the major driving factor for the market growth in the region. For instance, 223RaCl2 (Xofigo) is the first alpha-emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.
Moreover, according to the National Cancer Institute, the number of new cases of melanoma was 21.8 per 100,000 men and women, per year. Similarly, the rising prevalence of cancer is making it imperative for the healthcare professionals across Canada to increase the radiotherapy utilization for cancer treatment. This is directly affecting the growth of the alpha emitter market in the country.
Competitive Landscape
The global alpha emitter market is less competitive and consists of very few major players. Companies, like IBA Radiopharma Solutions, Bayer AG, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Telix Pharmaceuticals Ltd, RadioMedix Inc., and Fusion Pharmaceuticals hold the substantial market share in the global alpha emitter market.
A number of developments have been taking place in the market over recent years.
For example, in November 2017, Actinium Pharmaceuticals launched the AWE Program, aka Actinium Warhead Enabling Program, to enable collaborations based on its Actinium-225 Technology Platform. Whereas, in November 2017, Alpha Tau Medical entered a collaboration with IRST Italy to treat its first cancer patients. This is significant progress toward international expansion. This is also expected to enable the availability of Alpha DaRT radiotherapy all across Europe, Asia, as well as the United States.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Awareness About the Potential Benefits of Targeted Alpha Therapy
4.2.2 Increasing Number of Patients with Cardiac and Cancer Ailments
4.3 Market Restraints
4.3.1 Short Half-life of Radiopharmaceuticals
4.3.2 Stringent Regulatory Framework and Reimbursement Issues
4.3.3 Need for High Capital Investment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Type of Radionuclide
5.1.1 Terbium (Tb-149)
5.1.2 Astatine (At-211)
5.1.3 Bismuth (Bi-212)
5.1.4 Actinium (Ac-225)
5.1.5 Radium (Ra-223)
5.1.6 Lead (Pb-212)
5.1.7 Bismuth (Bi -213)
5.2 Medical Application
5.2.1 Glioma
5.2.2 Melanoma
5.2.3 Pancreatic Cancer
5.2.4 Ovarian Cancer
5.2.5 Thyroid
5.2.6 Bone Metastasis
5.2.7 Lymphoma
5.2.8 Endocrine Tumors
5.2.9 Other Medical Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Actinium Pharmaceutical Inc.
6.1.2 Alpha Tau Medical Ltd
6.1.3 Bayer AG
6.1.4 Fusion Pharmaceuticals
6.1.5 IBA Radiopharma Solutions
6.1.6 RadioMedix Inc.
6.1.7 Telix Pharmaceuticals Ltd
7. Market Opportunities and Future Trends
Market Segmentation
- Type of Radionuclide
Terbium (Tb-149)
Astatine (At-211)
Bismuth (Bi-212)
Actinium (Ac-225)
Radium (Ra-223)
Lead (Pb-212)
Bismuth (Bi -213)
Medical Application
Glioma
Melanoma
Pancreatic Cancer
Ovarian Cancer
Thyroid
Bone Metastasis
Lymphoma
Endocrine Tumors
Other Medical Applications
Geography
North America
United States
Canada
Mexico - Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America